Tag Archives: Dr. Brian G. Feagan MD

Boehringer Ingelheim: Risankizumab (formerly BI 655066) shown to be more effective than placebo in patients with moderately-to-severely active Crohn’s disease

Posted on 27, May 2016 by

After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment with one or more TNF antagonists,  achieved clinical remission with risankizumab compared with placebo1 Endoscopic remission was achieved in 15% … Read the full press release →

Posted in Germany, Healthcare, Pharma & Biotech, Science

Tagged , ,